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Abstract
Background With the easy availability of thyroid hormone
assays, thyroid disorders are now recognised even in a
subclinical state. However, patients are still seen with advanced
manifestations of the disease, particularly in developing
countries. This observational study analysed the predictors of
outcome in patients with myxoedema coma and tested the
validity of different modules to define morbidity and mortality in
these patients.
Methods Twenty-three consecutive patients with myxoedema
coma who presented from January 1999 to August 2006 were
studied. The thyroid function test and random serum cortisol
were measured in all patients at the time of admission. Patients
were given oral or intravenous (IV) thyroxine with intention to
treat with the latter according to availability. Various modules
that predict outcome, including Glasgow Coma Scale (GCS),
Acute Physiology and Chronic Health Evaluation II (APACHE II)
score, and Sequential Organ Failure Assessment (SOFA) score,
were analysed. SOFA score was repeated every 2 days until the
time of discharge or demise.
Results Twenty-three patients (20 women; 87%) of 59.5 ± 14.4
years of age (range, 30 to 89 years) were seen during the study
period. Nine (39%) patients were diagnosed with
hypothyroidism for the first time at the time of presentation of
myxoedema coma, whereas 14 (70%) were diagnosed with
hypothyroidism previously. However, the treatment defaulters
presented early to the hospital and had more severe
manifestations than de novo subjects. Nineteen (82%) had
thyroprivic (primary) and 4 (17%) had trophoprivic (secondary)
hypothyroidism. Fifteen (65%) patients presented in the winter
and in 17 (74%) sepsis was the major accompanying
comorbidity. Twelve (52%) had a history of diuretic use, thereby
delaying the initial diagnosis. Patients who received oral L-
thyroxine had no difference in outcome from those receiving IV
thyroxine. Twelve (52%) subjects died and sepsis was the
predominant cause of death. Various predictors of mortality
included hypotension (p = 0.01) and bradycardia (p = 0.03) at
presentation, need for mechanical ventilation (p  = 0.00),
hypothermia unresponsive to treatment (p = 0.01), sepsis (p =
0.01), intake of sedative drugs (p = 0.02), lower GCS (p =
0.03), high APACHE II score (p = 0.04), and high SOFA score
(p = 0.00). However, SOFA score was more effective than other
predictive models as baseline and day 3 SOFA scores of more
than 6 were highly predictive of poor outcome.
Conclusion L-Thyroxine treatment defaulters had more severe
manifestations compared with de novo subjects. Outcome was
not influenced by either aetiology or route of administration of L-
thyroxine, and SOFA score was the best outcome predictor
model.
Introduction
Myxoedema coma is an uncommon and life-threatening form
of long-standing, neglected, untreated hypothyroidism with
physiological decompensation [1]. This endocrine crisis usu-
ally occurs in elderly women and is precipitated by a second-
ary insult such as cold exposure, infection, drugs such as
sedative-hypnotics, lithium overdoses, and associated sys-
temic diseases [1,2]. Clinically, it is characterised by lethargy,
APACHE II = Acute Physiology and Chronic Health Evaluation II; ECG = electrocardiogram; GCS = Glasgow Coma Scale; IV = intravenous; SD = 
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myxoedematous manifestation, and altered sensorium in the
form of stupor, delirium, or coma. Due to widespread use of
screening tests for thyroid dysfunctions and hence the early
diagnosis even at the subclinical state, this entity has become
rare in Western countries. In developing countries, recognition
of this entity is hampered by its slow onset, lack of knowledge
among physicians and patients, and absence of cost-effective
guidelines to screen for subclinical thyroid diseases. There-
fore, patients presenting with florid manifestations of the dis-
ease are not uncommon. The incidence of myxoedema coma
in European countries is 0.22 per million per year [3]; however,
no such epidemiological data are available from the Indian
subcontinent. Review of the literature suggests that most of
the cases of myxoedema coma are isolated case reports or a
handful of series comprising only a few patients [4-16]. Myxo-
edema coma, if not appropriately treated, has been associated
with progressive multi-organ dysfunction and mortality. The
predictors of mortality modules used are Glasgow Coma
Scale (GCS) and Acute Physiology and Chronic Health Eval-
uation II (APACHE II) and Sequential Organ Failure Assess-
ment (SOFA) scores. However, GCS and APACHE II score
are assessed only at baseline and do not account for subse-
quent morbidity. On the contrary, SOFA score assesses the
cumulative morbidity and mortality during hospital stay. The
present study analysed the presentation and factors predict-
ing outcome of the patients with myxoedema coma and tested
the validity of various available outcome predictor models to
define morbidity and mortality in these patients.
Materials and methods
This prospective observational study includes consecutive
patients with myxoedema coma who presented to our institute
from January 1999 to August 2006. The study was approved
by institute's ethics committee, and written informed consent
was obtained from relatives of patients. Diagnosis of myxo-
edema coma was based on altered sensorium ranging from
obtundation and stupor to coma, hypothermia (core body tem-
perature of less than or equal to 35°C), a precipitating illness,
and low serum level of total or free thyroxine (T4) (total T4 of
less than 58 nmol/L and free T4 of less than 10.3 pmol/L, lower
limit of reference range). Sick euthyroid syndrome was
excluded by careful clinical examinations and appropriate
investigations. In all patients with primary hypothyroidism, a
thyroid-stimulating hormone (TSH) level of greater than 20
mU/L was taken along with low total and/or free T4, and in
patients with secondary hypothyroidism, structural abnormali-
ties of hypothalamo-pituitary area along with low total and/or
free T4 were considered diagnostic. Stupor was defined as a
lesser degree of unarousability in which the patient can be
awakened by external stimuli, accompanied by motor behav-
iour leading to the avoidance of uncomfortable or aggravating
stimuli. Obtundation was defined as easy arousal and the per-
sistence of alertness for brief periods. Both are always accom-
panied by some degree of confusion. Altered sensorium was
graded by GCS. Hypoventilation was defined as PaCO2 (par-
tial pressure of carbon dioxide, arterial) of greater than or equal
to 43 mm Hg. Glucocorticoid sufficiency was defined by ran-
dom plasma cortisol of greater than or equal to 350 nmol/L [9].
A blood sample for thyroid function, random cortisol, hemo-
gram, biochemistry, and arterial blood gas analysis was taken
in all patients prior to any therapy. The normal values of differ-
ent hormones were total triiodothyronine (T3) of 0.92 to 2.78
nmol/L, free T3 of 0.22 to 6.78 pmol/L, total T4 of 58 to 140
nmol/L, free T4 of 10.3 to 35 pmol/L, TSH of 0.15 to 4.55 mU/
L, and random plasma cortisol of 360 to 900.0 nmol/L. The
patients were treated with two regimens of L-T4: either an ini-
tial loading dose of 500 μg of oral L-T4 tablets (Eltroxin; Glax-
oSmithKline India, Mumbai through a nasogastric tube
followed by 150 μg of maintenance dose or an initial intrave-
nous (IV) loading dose of 200 μg of L-T4 sodium Ben Venue
laboratories, Inc., Bedford OH 44146, UK) followed by 100
μg of IV L-T4 until they regained their vital functions and were
able to take oral medications. The choice for IV or oral route of
administration of L-T4 was not by design but was based on the
availability of IV T4, always with an intention to treat with the lat-
ter. All patients received 100 mg of IV bolus of hydrocortisone
followed by infusion at a rate of 4 mg/hour before the start of
L-T4 therapy until the results of plasma cortisol were available.
Morbidity and mortality were assessed by GCS and APACHE
II and SOFA scores. The SOFA score was calculated at
admission and every 2 days until discharge or death. The last-
day SOFA score was calculated in all cases. For a single miss-
ing value, replacement was calculated from the mean of the
sum of the results immediately preceding and following the
missing values. During the calculation of a score in a given day,
the worst values for each parameter were taken.
Statistical analysis
The SPSS (Statistical Program for Social Sciences) package,
Release 10.01 for PC Windows (SPSS Inc., Chicago, IL,
USA), was used for data analysis. In addition to descriptive
statistics, the chi-square test was used to assess the associa-
tion between categorical variables. The t test was used to
compare the means between the continuous variables. Where
the data were skewed, a non-parametric test such as the
Mann-Whitney U test was used for comparison. The multiple
linear regression model was used with death as the dependent
variable and a number of other variables such as hospital stay,
stoppage of L-T4, use of IV T4, GCS, and SOFA score, and so
on, as independent variables. A P value of less than 0.05 was
used as the criterion of statistical significance. At an alpha of
less than 0.05, the study had a power of 90% in detecting the
difference in SOFA score on day 3 between the survivors and
those who died. All data are presented as mean ± standard
deviation (SD) unless otherwise indicated.Available online http://ccforum.com/content/12/1/R1
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Results
Twenty-three patients (20 women; 87%) of 59.5 ± 14.8 years
of age (range, 30 to 89 years) were included in the present
study. The mean lag time between the onset of symptoms and
hospitalisation was 10.5 ± 9.7 days (range, 1 to 45 days).
Nine (39%) patients were diagnosed with hypothyroidism for
the first time (de novo group) and 14 (61%) were previously
diagnosed (defaulter group). Nineteen (83%) patients had pri-
mary hypothyroidism and 4 (17%) had secondary hypothy-
roidism. Of them, 3 had Sheehan syndrome and 1 had non-
functioning pituitary adenoma. Fifteen patients presented in
the winter and cold exposure was considered to be a major
precipitating factor. Sedative hypnotics and lithium overdose
were considered to be a precipitating factor in 3 patients and
1 patient, respectively. Infection was the major accompanying
comorbidity in 17 (74%) patients, including bacterial pneumo-
nia in 13, urosepsis in 2, and 1 each with viral gastroenteritis
and hepatitis. Twelve patients had a history of diuretic use for
their edematous states without correct diagnosis of hypothy-
roidism. Eight patients had tense ascites at the time of presen-
tation, and 2 patients had myxoedema ileus as a presenting
manifestation. Sixteen (69%) patients were deeply comatose
and 7 were obtunded at the time of presentation. Myxoedema-
tous skin was present in all patients but was more marked in
patients with primary hypothyroidism, and hypothermia was
accompanied in all patients. The presenting manifestations
and clinical profile are summarised in Table 1.
Biochemistry showed mean (± SD) serum sodium of 134.2 ±
10.4 mEq/L (range, 118 to 160 mE q/L). The mean (± SD)
serum T4 and TSH in patients with primary hypothyroidism
were 19.07 ± 14.59 nmol/L and 68.9 ± 41.5 mU/L, respec-
tively. In secondary hypothyroidism, mean (± SD) serum T4 and
TSH were 23.04 ± 15.36 nmol/L and 3.17 ± 3.47 mU/L (p =
0.08 and 0.005), respectively. The mean (± SD) serum T4 in
the defaulter group was 18.56 ± 12.68 nmol/L as compared
with 22.78 ± 11.52 nmol/L in the de novo group (p = 0.82).
The mean (± SD) random serum cortisol was 390.2 ± 82.1
nmol/L, and 7 were glucocorticoid-deficient. Four patients had
associated hypoglycaemia at the time of presentation.
Eleven patients had cardiomegaly on chest x-ray either due to
dilated cardiomyopathy (3) or pericardial effusion (8), and 17
had an abnormal electrocardiogram (ECG). The various ECG
abnormalities included low voltage complex, sinus bradycardia
non-specific ST&T changes, left ventricular hypertrophy, atrial
arrhythmias, and bundle branch block in decreasing order.
Eleven patients had hypoventilation, 8 had CO2 narcosis, and
13 had coagulopathy.
Those who stopped L-T4 (defaulter group) presented early to
the hospital and had advanced manifestations as opposed to
those who presented for the first time (de novo group) (7.5 ±
5.9 and 15.1 ± 12.8 days, respectively; p = 0.06). The clinical
manifestations in the defaulter group were more severe as
compared with the de novo group: bradycardia (heart rate of
60 ± 15 beats per minute versus 82 ± 12 beats per minute; P
= 0.002), lesser score in GCS (6.0 ± 3.0 versus 8.1 ± 3.5; P
= 0.18), number of patients requiring mechanical ventilation
(71.4% versus 22.2%; P = 0.036), and higher mortality (10
versus 2; p = 0.036).
There was no significant difference among any parameters
between primary and secondary hypothyroidism except that
the patients with primary hypothyroidism had more severe skin
manifestations, higher TSH level, and relatively lower serum T4
level.
Only 11 (45%) out of these 23 patients could survive, with a
mean duration of hospital stay of 15.9 ± 18.9 days (range, 2
to 90 days) after the start of treatment. Nine (50%) out of 18
patients who received oral T4 died, whereas 3 out of 5 (60%)
died in the IV T4 group (p = 0.782). However, there was no dif-
ference in clinical and biochemical parameters in the IV or oral
T4 group. Although more patients receiving IV T4 had sepsis,
increased need for mechanical ventilation, longer duration of
hospital stay, and higher mortality, none of these could reach
statistical significance.
The most common organ dysfunction at presentation was res-
piratory failure, and the most common new organ dysfunction
during hospital stay was coagulopathy. Causes of death
included sepsis, upper gastrointestinal bleed, and respiratory
failure. The various factors associated with increased mortality
were hypotension (r = 0.51; p = 0.01) and bradycardia (r =
0.44; p = 0.03) at presentation, need for mechanical ventila-
tion (r = 0.65; p = 0.00), hypothermia unresponsive to treat-
ment (r  = 0.51; p  = 0.01), sepsis (r  = 0.50; p  = 0.01),
stoppage of L-T4 (r = 0.48; p = 0.01), intake of sedative drugs
(r = 0.47; p = 0.02), lower GCS (r = 0.45; p = 0.03), higher
APACHE II score (r = 0.51; p = 0.04), and higher SOFA score
(r = 0.51; p = 0.00) (Table 2).
On analysing the different prediction models of morbidity and
mortality, APACHE II score and GCS had a significant differ-
ence between survivors and non-survivors. However, the
SOFA prediction module at baseline was not different
between the two groups. The baseline and day 3 SOFA
scores of greater than or equal to 6 predicted mortality with a
sensitivity of 91.7% and a specificity of 100%. Similarly higher
the means SOFA score higher was the mortality (Figure 1) All
of the prediction modules are summarised in Table 3, and
receiver operating characteristic analysis is drawn to assess
the area under the curve for the SOFA scores (Figure 2).
Discussion
The present study showed that patients who were previously
diagnosed and non-compliant with the L-T4 treatment had
more severe manifestations at presentation and higher mortal-
ity in comparison with those who were diagnosed as havingCritical Care    Vol 12 No 1    Dutta et al.
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Table 1
Clinical and laboratory findings in 23 patients with myxoedema coma
Subject number Age, years Gender Aetiology of 
hypothyroidism
Precipitating factors Associated comorbodities L-T4 route Outcome
1 46 Female Secondary Pneumonia T2DM, complete heart block Oral Died
2 70 Female Primary Pneumonia T2DM, nephropathy Oral Died
3 70 Female Primary Pneumonia, cold exposure Old stroke, HTN, DIC Oral Died
4 58 Male Primary Cold exposure, stoppage of 
L-T4
Old Pott's spine, ascites Oral Survived
5 70 Female Secondary Cold exposure T2DM, HTN Oral Survived
6 72 Female Primary Pneumonia, sedative T2DM, acute renal failure Died
7 55 Male Primary Urosepsis OSA, HTN, CLD cortical 
critical care neuropathy
Oral Survived
8 60 Female Primary Cellulitis, 
pseudomembranous colitis
DCM, CHF, DIC Oral Died
9 59 Female Secondary Pneumonia Anaemia, sepsis, shock Oral Died
10 45 Female Secondary Pneumonia Anaemia, pericardial effusion Died
11 42 Female Primary Sedative, cold exposure, 
hypoglycaemia
Septic shock, respiratory 
failure
Oral Survived
12 48 Female Primary Cold exposure DCM, CHF Oral Survived
13 89 Female Primary Acute, cold exposure, 
hypoglycaemia
Sepsis, refractory 
hypotension
Oral Died
14 50 Female Primary Pneumonia, overdose Atrial fibrillation, right bundle 
branch block, DIC, T2DM
Oral Survived
15 30 Female Primary Sepsis, DIC, T2DM Oral Died
16 52 Female Primary Pneumonia T2DM, extrahepatic portal 
vein obstruction, sepsis
IV Died
17 60 Female Primary Cold exposure, pneumonia 
acute gastroenteritis, viral 
hepatitis
Bronchial asthma, sepsis, 
DIC
IV Died
18 85 Male Primary Urosepsis, hypoglycaemia, 
cold exposure
T2DM, HTN, benign 
prostatic hyperplasia, 
chronic kidney disease, DIC, 
refractory seizures
IV Died
19 83 Female Primary Cerebrovascular accident, 
pneumonia, sedative, cold 
exposure
Hypotension, bronchial 
asthma, OSA
IV Survived
20 60 Female Primary Pneumonia, upper 
gastrointestinal bleed
HTN, CAD, chronic 
obstetric airway disease, 
CLD, T2DM, rheumatoid 
arthritis
IV Survived
21 50 Female Primary Cold exposure T2DM, HTN, anaemia, old 
pulmonary tuberculosis, 
pericardial effusion
Oral Survived
22 70 Female Primary Cold exposure, urosepsis, 
sedative
T2DM, HTN, CAD, 
refractory seizures,
Oral Survived
23 45 Female Primary Cold exposure DCM, pericardial effusion Oral Survived
CAD, coronary artery disease; CHF, congestive cardiac failure; CLD, chronic liver disease; DCM, dilated cardiomyopathy; DIC, disseminated 
intravascular coagulation; HTN, hypertension; IV, intravenous; L-T4, L-thyroxine; OSA, obstructive sleep apnoea; T2DM, type 2 diabetes mellitus.Available online http://ccforum.com/content/12/1/R1
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hypothyroidism for the first time. The aetiology of hypothy-
roidism (primary versus secondary) and route of administration
of L-T4 (oral versus IV) had no influence on outcome. Among
various outcome prediction models for critical care illness, the
SOFA score was found to correlate best with mortality in these
patients.
As hypothyroidism is more common in elderly women, most of
our patients were older females (87%) [4]. As in previous
reports, the majority of our patients presented in the winter and
hypothermia was a frequent accompaniment [4] as cold
weather lowers the threshold for encephalopathy in patients
with hypothyroidism and this is possibly attributed to the failure
of thermoregulatory compensatory mechanisms. In agreement
with the published literature, chest and genitourinary infec-
tions were the most common comorbidities and/or precipitat-
ing factors in the present study [1,3,5,6]. Nearly half of our
patients were inappropriately treated with diuretics for edema-
tous state by primary care physicians and that masked the
myxoedematous manifestations and posed a difficulty in mak-
ing an early diagnosis of hypothyroidism.
The prevalence of secondary hypothyroidism in myxoedema
coma has been reported to be 5% to 25% [5,7,8]. In our
study, 4 (18%) patients had secondary hypothyroidism and all
had hypothyroid encephalopathy as a presenting manifesta-
tion of their pituitary disease. Due to the paucity of cases, none
of the previous studies except one had compared the clinical
parameters in primary and secondary hypothyroid patients
with myxoedema coma [5]. As expected, the myxoedematous
manifestations were very subtle and these subjects had rela-
tively higher T4 levels as compared with patients with primary
hypothyroidism as TSH-independent production of T4 contin-
ues in patients with secondary hypothyroidism [10].
An appreciable difference in presenting manifestations, labo-
ratory parameters, and outcome was observed in those who
were defaulters as opposed to those who presented de novo
as having myxoedema coma. However, this issue has not been
examined in earlier studies. The defaulter patients had a lower
mean heart rate and relatively lower serum T4 and the majority
of them required mechanical ventilation and had a higher mor-
tality. They also had lower scores on GCS, comparable
APACHE II scores, and showed better SOFA scores in com-
parison with the patients who were diagnosed as hypothyroid
at the first presentation of myxoedema coma. This may be
attributed to the fact that the non-compliant patients had abso-
lute deficiency of thyroid hormones as compared with those
Table 2
Factors predicting mortality in survivors and non-survivors
Survivors (n = 11) Non-survivors (n = 12) P value
Age, years 57.36 ± 12.55 61.50 ± 16.97 0.517
Lag time, days 10.64 ± 6.39 10.33 ± 12.29 0.942
Stoppage of L-thyroxine 4 10 0.036a
Use of sedatives 7 12 0.037a
Heart rate, beats per minute 77.45 ± 14.45 61.25 ± 18.13 0.028a
Mean blood pressure, mm Hg 117.64 ± 24.88 90.45 ± 32.28 0.039a
Thyroxine, nmol/L 19.84 ± 19.45 23.42 ± 14.46 0.616
Thyroid-stimulating hormone, mU/L 56.99 ± 39.40 57.87 ± 51.99 0.964
Glucocorticoid deficiency 2 5 0.371
Sepsis 6 1 0.027a
Unresponsive hypothermia 5 10 0.027a
Mechanical ventilation 2 10 0.003a
Intravenous thyroxine 2 3 0.9
Glasgow Coma Scale 8.55 ± 3.39 5.50 ± 2.47 0.022a
APACHE II score 12.09 ± 4.95 18.08 ± 8.02 0.045a
SOFA score, baseline 8.5 ± 3.1 6.6 ± 3.9 0.22
SOFA score, minimum 1.45 ± 1.04 7.58 ± 3.00 0.000a
SOFA score, maximum 7.36 ± 3.38 15.17 ± 1.99 0.000a
Hospital stay, days 20.73 ± 24.67 11.42 ± 11.09 0.249
APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ Failure Assessment.Critical Care    Vol 12 No 1    Dutta et al.
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presenting for the first time as having myxoedema coma but
who possibly had borderline thyroid hormone reserve.
The dose and route of administration of L-T4 in myxoedema
coma have always been a matter of debate. The available liter-
ature on thyroid hormone replacement therapy in patients with
myxoedema coma comprises three categories: IV T4, oral T4,
and oral or IV T3 [11]. IV administration of T4 has certain advan-
tages, including predictable effect, early saturation of binding
sites, and swift replenishment of the thyroid hormone pool
[11]. In spite of the above-mentioned advantages with IV T4, it
has been refuted by other investigators that oral administration
of L-T4 is associated with variable but quick clinical response,
even in patients with myxoedema ileus [11-13]. The recom-
mended initial IV T4 bolus dose varies from 100 to 500 μg fol-
lowed by daily maintenance of 50 to 100 μg until sensorium
improves [5,14-16]. However, the cause of coma in all
patients may not be uniform, and minor precipitating illness or
comorbidity can lead to coma. Therefore, not every patient will
require a large loading dose [6,17,18]. Similarly, in last four
decades, there has been a considerable change in supportive
medical care, thereby decreasing the role of high-dose T4.
Given the total body store, daily T4 production rate, the asso-
ciated cardiac comorbidities, and the fact that the usual IV
loading dose of T4 was approximately one half to two thirds of
the oral dose, we were compelled to use 200 μg of L-T4 as the
IV loading dose. We preferred an oral dose of 500 μg as the
loading dose since a dose of more than 500 μg/day of oral L-
T4 was associated with a fatal outcome within 1 month of treat-
ment in one study [6]. This type of approach is supported by a
recent publication by Wartofsky [4]. None of the available
studies had compared IV T4 with oral T4. Due to the low avail-
ability of IV T4 in our country, the present study provides an
opportunity not by design, but by default, to analyse this issue.
However, only five patients could receive IV T4 and this is a
small number to make any definitive conclusion. Coinciden-
tally, the patients receiving IV T4 were more critically ill than the
oral T4 group, but mortality could not reach statistical signifi-
cance between the two groups.
The proponents of T3 therapy argue that the onset of action of
T3 is rapid, that peripheral conversion of T4 to T3 is hampered
in the sick hypothyroid state, and that it has an earlier benefi-
cial effect on neuropsychiatric symptoms as it crosses the
blood-brain barrier more rapidly than T4 does [4]. However,
due to the non-availability of T3, we had not used it in our
patients.
Patients with long-standing hypothyroidism may have associ-
ated glucocorticoid deficiency; therefore, glucocorticoid sup-
port is recommended [11]. In our study, all patients received
glucocorticoid therapy, but there was no difference in out-
come between glucocorticoid-deficient and glucocorticoid-
sufficient subjects.
Prediction of outcome is important both in emergency services
and intensive care units. Currently available outcome predic-
tion models such as APACHE II score, GCS, SAPS (Simpli-
fied Acute Physiology Score), and MPM (Mortality Probability
Model) systems calculate a prediction based on values taken
in first 24 hours of admission, but not later [19,20]. They are
best suited for a mixed pool of patients suffering from a variety
of disease conditions, but their validity on a day-to-day basis or
for a homogenous group of patients such as those with myxo-
edema coma is questionable. Unlike these models, the SOFA
score is validated for assessing and monitoring organ dysfunc-
tion because organ failure is a continuous process rather than
an 'all or none' phenomenon [20,21]. The initial SOFA score
can be used to predict the degree of organ dysfunction or fail-
ure present at admission, delta SOFA score during hospital
stay, and total maximum SOFA score represents the cumula-
tive organ dysfunction experienced by the patients [20-22]. In
our experience, this was the best module for predicting mortal-
ity and morbidity.
The prognosis of patients with myxoedema coma is difficult to
predict due to the rarity of the condition. Before 1964, the
mortality rate was as high as 80% [23]. The mortality rate in
the present study was 52.2%, which is similar to that reported
by Arlot and colleagues [13]. The improvement in outcome is
attributed to early diagnosis, better supportive care, and use of
IV T4. In previous studies, poor predictors of outcome included
advanced age, bradycardia, persistent hypothermia, level of
sensorium, and high APACHE II score at presentation
Figure 1
Mean Sequential Organ Failure Assessment (SOFA) score and mortal- ity in myxoedema coma Mean Sequential Organ Failure Assessment (SOFA) score and mortal-
ity in myxoedema coma. The higher the SOFA score, the higher the 
mortality.Available online http://ccforum.com/content/12/1/R1
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[5,11,22,24]. Our study is in agreement with previous studies
in this aspect, except advanced age, which was comparable
between survivors and non-survivors. Additionally, low mean
blood pressure, requirement for mechanical ventilation, pre-
cipitation of myxoedema coma by use of sedatives, accompa-
nying sepsis, and baseline and mean SOFA scores of greater
than or equal to 6 were predictive of mortality.
Figure 2
ROC curve showing sensitivity & specificity of various SOFA scores ROC curve showing sensitivity & specificity of various SOFA scores.
Table 3
Sensitivity and specificity of SOFA score, GCS, and APACHE II score in predicting mortality in myxoedema coma patients
Score Died Survived Sensitivity 
(percentage)
Specificity 
(percentage)
Positive PV 
(percentage)
Negative PV 
(percentage)
Accuracy 
(percentage)
SOFA score, baseline ≥6 11/12 5/11 91.7 54.5 68.8 85.7 73.9
SOFA score, day 3 ≥6 12/12 2/11 100 81.8 85.7 100 91.3
SOFA score, maximum ≥12 12/12 1/11 100 90.9 92.3 100 95.7
SOFA score, delta ≥3.5 9/12 0/11 75.0 100 100 78.6 87.0
SOFA score, mean ≥7 12/12 0/11 100 100 100 100 100
GCS ≤8 11/12 4/11 91.7 63.6 73.3 87.5 78.3
APACHE II score ≥15 8/11 3/11 66.7 72.7 72.7 66.7 69.6
APACHE II, Acute Physiology and Chronic Health Evaluation II; GCS, Glasgow Coma Scale; PV, predictive value; SOFA, Sequential Organ 
Failure Assessment.Critical Care    Vol 12 No 1    Dutta et al.
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Conclusion
The patients who were non-compliant to L-T4 therapy had ear-
lier presentation, more severe manifestations, and higher mor-
tality compared with de novo subjects. Outcome was not
influenced by aetiology or route of administration of L-T4, and
SOFA score was the best outcome-predicting model.
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Key messages
￿ L-Thyroxine  treatment  defaulters had more florid mani-
festations and poorer outcomes as compared with 
those who were diagnosed for the first time.
￿  Sepsis is a major accompanying comorbidity in patients 
with myxoedema coma and usually culminates in death.
￿  Outcome was not influenced by the aetiology (primary 
versus secondary) or the route of administration of L-
thyroxine (intravenous versus oral).
￿  Of the available predictor modules, Sequential Organ 
Failure Assessment was more effective than the others.